TITLE

Israeli law too much Bolar for PhRMA

PUB. DATE
April 1998
SOURCE
Medical Marketing & Media;Apr98, Vol. 33 Issue 4, p32
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Comments on the views of PhRMA spokesman Jeff Trewhitt of the patent reform legislation enacted by the Israeli Knesset. Reference to the United States (U.S.) statue allowing generics to make drugs for review purposes; Other information on the issue.
ACCESSION #
532590

Tags: PATENTS

 

Related Articles

  • The Community Patent: Thirty Years of Planning Grinds to a Halt. Carter, Stephen // Medical Device Technology;Sep2003, Vol. 14 Issue 7, p38 

    Explores the controversies associated with the Community Patent, a unitary patent right with effect throughout Europe. Problems with the European patent system; Initial proposal of English as the language for the Community Patent; Agreement that the applicant must file translations of the...

  • Some Patent Reviews in Trouble in Europe.  // Corporate Legal Times;Dec2001, Vol. 11 Issue 121, pDWB4 

    Reports the rise of patent applications received by the European Patent Office (EPO). Implications of the increase for United States-based multinationals seeking patent reviews; Provisions of the Patent Cooperation Treaty; Factors causing the delay on the review of patents.

  • Picking the proper patent. Cannon, Karl R.; Mraz, Stephen // Machine Design;02/20/97, Vol. 69 Issue 4, p110 

    Discusses various types of patents. Includes utility patents for devices, compositions and processes; Design patents for ornamental design; Plant patents for certain asexually produced plants; Provisions of patents; Risks in applying for design patents.

  • Patents.  // New Orleans CityBusiness (1994 to 2008);07/21/97, Vol. 18 Issue 3, p36 

    Presents a listing of patents filed in New Orleans, Louisiana, in the `Official Gazette of the United States Patent & Trademark Office,' on May 27, 1997.

  • Secrecy loophole puts public at risk. Fox, B. // New Scientist;1/25/92, Vol. 133 Issue 1805, p32 

    Reports that patents for devices that could protect the public from terrorists are passing through a loophole in the European patent system. European Patent Office takes no responsibility for secrecy; Responsibility rests with individual countries; Patent Office has no clear rules on the safety...

  • US gene plan `makes a mockery of patents.' Coghlan, A. // New Scientist;2/22/92, Vol. 133 Issue 1809, p10 

    Reports on the concern expressed by European researchers over the large amount of patents American researchers have applied for on newly isolated stretches of DNA. They believe Americans do not know the entire sequences or functions of the genesand this makes a mockery of the concept of a patent.

  • Still pending in the old Soviet Union.  // New Scientist;2/29/92, Vol. 133 Issue 1810, p28 

    Reports on the current havoc that the break-up of the Soviet Union has had on the world of patents. The Soviet certification scheme ended in July 1991 and was to be replaced with some kind of Soviet Commonwealth office; State Information Centre in Slovenia has taken on the job of granting...

  • Fast patent record.  // New Scientist;2/29/92, Vol. 133 Issue 1810, p28 

    Reports on a patent Du Pont received from the United States Patent Office which took only 29 weeks to obtain. Inventors upset by their notoriously slow pace of granting patent applications will be able to remind examiners of Du Pont's star treatment.

  • Military secrets.  // New Scientist;2/29/92, Vol. 133 Issue 1810, p28 

    Lists a number of patents for military inventions filed as far back as 1949 and until now classified as secret. Proximity fuses for bombs and shells; Missile guidance system; Research work on a range of potassium salts of nitrated phenols.

  • Ministers move to limit genome patents. Charles, D.; Coghlan, A. // New Scientist;3/14/92, Vol. 133 Issue 1812, p9 

    Reports on an international row that has developed over the practice of issuing patents for segments of DNA from the human genome. Reasons why critics disapprove of the practice; Who is involved; Response from biotechnical companies.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics